Explore Research Materials The peptide industry was shaken recently when Eli Lilly filed lawsuits against several companies accused of selling products purported to contain Retatrutide, the company's highly anticipated investigational obesity and diabetes drug. Retatrutide has generated significant attention because of promising clinical trial results, but it has not yet received FDA approval for human use. According to Lilly, the lawsuits target companies that are allegedly

Tirzepatide is a relatively new medication that has attracted significant attention in medical research because of its ability to improve blood sugar control and promote substantial weight loss. Unlike earlier therapies that target only the GLP-1 hormone pathway, tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors. This dual action appears to enhance its effectiveness in treating metabolic disease. Clinical trials have shown i